Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: State of the science

Joshua L. Weintraub, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma. There is strong scientific rationale for combination therapy: transarterial chemoembolization produces ischemia and stimulates hypoxia-inducible factor-1α, resulting in a local and systemic upregulation of vascular endothelial growth factor (VEGF), which can increase tumor angiogenesis. This upregulation can theoretically be counteracted with the multikinase inhibitor sorafenib, which is thought to act directly on platelet-derived growth factor, Raf kinase, and VEGF receptors. The potential of this approach has not yet been fully realized in clinical trials, and many unanswered questions remain. This review article discusses the state of the science of arterial locoregional therapies and sorafenib.

Original languageEnglish (US)
Pages (from-to)1123-1134
Number of pages12
JournalJournal of Vascular and Interventional Radiology
Volume24
Issue number8
DOIs
StatePublished - Aug 1 2013

Fingerprint

Hepatocellular Carcinoma
Up-Regulation
raf Kinases
Hypoxia-Inducible Factor 1
Vascular Endothelial Growth Factor Receptor
Platelet-Derived Growth Factor
Vascular Endothelial Growth Factor A
Patient Care
Therapeutics
Ischemia
Clinical Trials
sorafenib
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

@article{94bbb9a7a50a41019cd7a3c9e6e68dfb,
title = "Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: State of the science",
abstract = "The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma. There is strong scientific rationale for combination therapy: transarterial chemoembolization produces ischemia and stimulates hypoxia-inducible factor-1α, resulting in a local and systemic upregulation of vascular endothelial growth factor (VEGF), which can increase tumor angiogenesis. This upregulation can theoretically be counteracted with the multikinase inhibitor sorafenib, which is thought to act directly on platelet-derived growth factor, Raf kinase, and VEGF receptors. The potential of this approach has not yet been fully realized in clinical trials, and many unanswered questions remain. This review article discusses the state of the science of arterial locoregional therapies and sorafenib.",
author = "Weintraub, {Joshua L.} and Riad Salem",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.jvir.2013.01.494",
language = "English (US)",
volume = "24",
pages = "1123--1134",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "8",

}

Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy : State of the science. / Weintraub, Joshua L.; Salem, Riad.

In: Journal of Vascular and Interventional Radiology, Vol. 24, No. 8, 01.08.2013, p. 1123-1134.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy

T2 - State of the science

AU - Weintraub, Joshua L.

AU - Salem, Riad

PY - 2013/8/1

Y1 - 2013/8/1

N2 - The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma. There is strong scientific rationale for combination therapy: transarterial chemoembolization produces ischemia and stimulates hypoxia-inducible factor-1α, resulting in a local and systemic upregulation of vascular endothelial growth factor (VEGF), which can increase tumor angiogenesis. This upregulation can theoretically be counteracted with the multikinase inhibitor sorafenib, which is thought to act directly on platelet-derived growth factor, Raf kinase, and VEGF receptors. The potential of this approach has not yet been fully realized in clinical trials, and many unanswered questions remain. This review article discusses the state of the science of arterial locoregional therapies and sorafenib.

AB - The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma. There is strong scientific rationale for combination therapy: transarterial chemoembolization produces ischemia and stimulates hypoxia-inducible factor-1α, resulting in a local and systemic upregulation of vascular endothelial growth factor (VEGF), which can increase tumor angiogenesis. This upregulation can theoretically be counteracted with the multikinase inhibitor sorafenib, which is thought to act directly on platelet-derived growth factor, Raf kinase, and VEGF receptors. The potential of this approach has not yet been fully realized in clinical trials, and many unanswered questions remain. This review article discusses the state of the science of arterial locoregional therapies and sorafenib.

UR - http://www.scopus.com/inward/record.url?scp=84880745694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880745694&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2013.01.494

DO - 10.1016/j.jvir.2013.01.494

M3 - Review article

C2 - 23562168

AN - SCOPUS:84880745694

VL - 24

SP - 1123

EP - 1134

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 8

ER -